Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BF-200 ALA versus Metvix and placebo for actinic keratosis with photodynamic therapy
2007-006854-24Phase 3Completed
- Sponsor
- Biofrontera
- Start
- Feb 2008
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of 5-aminolevulinic acid, methyl aminolevulinate and Placebo-COD Research Private Ltd in actinic keratosis (AK) (3 arms), sponsored by Biofrontera. Primary endpoints: Overall patient complete response rate and Missing data handling for primary endpoint. Started Feb 2008; status: completed.
02
Drugs
5-aminolevulinic acidmethyl aminolevulinatePlacebo-COD Research Private Ltd
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2007-006854-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006854-24.